{"id":305121,"date":"2026-10-13T12:17:55","date_gmt":"2026-10-13T06:47:55","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=305121"},"modified":"2026-10-13T12:17:55","modified_gmt":"2026-10-13T06:47:55","slug":"kopran-vs-syncom-formulations-vs-shree-ganesh-remedies","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/kopran-vs-syncom-formulations-vs-shree-ganesh-remedies\/","title":{"rendered":"Kopran vs Syncom Formulations vs Shree Ganesh Remedies: Which Stock Should You Track"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Kopran PE 49.10, mkt cap Rs 1,227 crore. Syncom Formulations (India) PE 25.91, mkt cap Rs 2,217 crore. Shree Ganesh Remedies PE 58.77, mkt cap Rs 907 crore.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">Kopran vs Syncom Formulations (India) vs Shree Ganesh Remedies is a side-by-side comparison of three companies from the pharma and biotech space. On this comparison, Kopran carries a market capitalisation of about Rs 1,227 crore, against Rs 2,217 crore for Syncom Formulations (India) and Rs 907 crore for Shree Ganesh Remedies, with return on equity of 4.85%, 18.42% and 10.90% respectively. Each company&#8217;s numbers are presented here without a declared preference, since the right stock depends on an investor&#8217;s own criteria.<\/p>\n<\/div>\n<p>Kopran vs Syncom Formulations (India) vs Shree Ganesh Remedies starts with the core numbers most investors compare within the pharma and biotech segment: market capitalisation, valuation multiples, profitability, dividend yield and the latest quarterly results. Figures below are sourced as of October 2026 and will shift with daily price moves.<\/p>\n<p>All three names sit in the pharma and biotech bucket, which makes them a natural set to place side by side rather than a random trio of unrelated businesses. The sections below cover the company profiles, a valuation table, the latest quarter and a five-quarter trend for revenue and net profit.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=kopran-vs-syncom-formulations-vs-shree-ganesh-remedies\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/kopran-vs-syncom-formulations-vs-shree-ganesh-remedies\/#Kopran_Syncom_Formulations_India_and_Shree_Ganesh_Remedies_Company_Overview\" title=\"Kopran, Syncom Formulations (India) and Shree Ganesh Remedies: Company Overview\">Kopran, Syncom Formulations (India) and Shree Ganesh Remedies: Company Overview<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/kopran-vs-syncom-formulations-vs-shree-ganesh-remedies\/#Kopran_vs_Syncom_Formulations_India_vs_Shree_Ganesh_Remedies_Valuation_and_Profitability_Snapshot\" title=\"Kopran vs Syncom Formulations (India) vs Shree Ganesh Remedies: Valuation and Profitability Snapshot\">Kopran vs Syncom Formulations (India) vs Shree Ganesh Remedies: Valuation and Profitability Snapshot<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/kopran-vs-syncom-formulations-vs-shree-ganesh-remedies\/#Kopran_vs_Syncom_Formulations_India_vs_Shree_Ganesh_Remedies_Latest_Quarterly_Results\" title=\"Kopran vs Syncom Formulations (India) vs Shree Ganesh Remedies: Latest Quarterly Results\">Kopran vs Syncom Formulations (India) vs Shree Ganesh Remedies: Latest Quarterly Results<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/kopran-vs-syncom-formulations-vs-shree-ganesh-remedies\/#Kopran_vs_Syncom_Formulations_India_vs_Shree_Ganesh_Remedies_Five-Quarter_Revenue_and_Net_Profit_Trend\" title=\"Kopran vs Syncom Formulations (India) vs Shree Ganesh Remedies: Five-Quarter Revenue and Net Profit Trend\">Kopran vs Syncom Formulations (India) vs Shree Ganesh Remedies: Five-Quarter Revenue and Net Profit Trend<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/kopran-vs-syncom-formulations-vs-shree-ganesh-remedies\/#What_Should_Investors_Look_at_Beyond_These_Numbers\" title=\"What Should Investors Look at Beyond These Numbers?\">What Should Investors Look at Beyond These Numbers?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/kopran-vs-syncom-formulations-vs-shree-ganesh-remedies\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/kopran-vs-syncom-formulations-vs-shree-ganesh-remedies\/#FAQs_on_Kopran_vs_Syncom_Formulations_India_vs_Shree_Ganesh_Remedies\" title=\"FAQs on Kopran vs Syncom Formulations (India) vs Shree Ganesh Remedies\">FAQs on Kopran vs Syncom Formulations (India) vs Shree Ganesh Remedies<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/kopran-vs-syncom-formulations-vs-shree-ganesh-remedies\/#What_is_the_market_cap_difference_between_Kopran_Syncom_Formulations_India_and_Shree_Ganesh_Remedies\" title=\"What is the market cap difference between Kopran, Syncom Formulations (India) and Shree Ganesh Remedies?\">What is the market cap difference between Kopran, Syncom Formulations (India) and Shree Ganesh Remedies?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/kopran-vs-syncom-formulations-vs-shree-ganesh-remedies\/#What_are_the_PE_and_PB_ratios_of_Kopran_Syncom_Formulations_India_and_Shree_Ganesh_Remedies\" title=\"What are the PE and PB ratios of Kopran, Syncom Formulations (India) and Shree Ganesh Remedies?\">What are the PE and PB ratios of Kopran, Syncom Formulations (India) and Shree Ganesh Remedies?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/kopran-vs-syncom-formulations-vs-shree-ganesh-remedies\/#Which_of_the_three_has_the_highest_ROE\" title=\"Which of the three has the highest ROE?\">Which of the three has the highest ROE?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/kopran-vs-syncom-formulations-vs-shree-ganesh-remedies\/#Which_of_these_three_stocks_pays_the_highest_dividend_yield\" title=\"Which of these three stocks pays the highest dividend yield?\">Which of these three stocks pays the highest dividend yield?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/kopran-vs-syncom-formulations-vs-shree-ganesh-remedies\/#What_is_the_debt_to_equity_ratio_for_Kopran_Syncom_Formulations_India_and_Shree_Ganesh_Remedies\" title=\"What is the debt to equity ratio for Kopran, Syncom Formulations (India) and Shree Ganesh Remedies?\">What is the debt to equity ratio for Kopran, Syncom Formulations (India) and Shree Ganesh Remedies?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/kopran-vs-syncom-formulations-vs-shree-ganesh-remedies\/#What_were_the_latest_quarterly_revenue_and_net_profit_of_Kopran_Syncom_Formulations_India_and_Shree_Ganesh_Remedies\" title=\"What were the latest quarterly revenue and net profit of Kopran, Syncom Formulations (India) and Shree Ganesh Remedies?\">What were the latest quarterly revenue and net profit of Kopran, Syncom Formulations (India) and Shree Ganesh Remedies?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/kopran-vs-syncom-formulations-vs-shree-ganesh-remedies\/#Does_this_comparison_recommend_one_of_Kopran_Syncom_Formulations_India_and_Shree_Ganesh_Remedies\" title=\"Does this comparison recommend one of Kopran, Syncom Formulations (India) and Shree Ganesh Remedies?\">Does this comparison recommend one of Kopran, Syncom Formulations (India) and Shree Ganesh Remedies?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Kopran_Syncom_Formulations_India_and_Shree_Ganesh_Remedies_Company_Overview\"><\/span><strong>Kopran, Syncom Formulations (India) and Shree Ganesh Remedies: Company Overview<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><strong>Kopran<\/strong> is a listed Indian company in the pharma and biotech space, tracked here on book value, return ratios and valuation alongside its peers in this comparison. It has a market capitalisation of about Rs 1,227 crore, a return on equity of 4.85% and a book value of Rs 109.74 per share. Its quarterly revenue moved from Rs 137.78 crore in June 2025 to Rs 156.04 crore in June 2026, a change of +13.3%.<\/p>\n<p><strong>Syncom Formulations (India)<\/strong> is a listed Indian company in the pharma and biotech space, tracked here on book value, return ratios and valuation alongside its peers in this comparison. It has a market capitalisation of about Rs 2,217 crore, a return on equity of 18.42% and a book value of Rs 4.41 per share. Its quarterly revenue moved from Rs 122.93 crore in June 2025 to Rs 133.36 crore in June 2026, a change of +8.5%.<\/p>\n<p><strong>Shree Ganesh Remedies<\/strong> is a listed Indian company in the pharma and biotech space, tracked here on book value, return ratios and valuation alongside its peers in this comparison. It has a market capitalisation of about Rs 907 crore, a return on equity of 10.90% and a book value of Rs 126.95 per share. Its quarterly revenue moved from Rs 25.33 crore in June 2025 to Rs 15.30 crore in June 2026, a change of -39.6%.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Kopran_vs_Syncom_Formulations_India_vs_Shree_Ganesh_Remedies_Valuation_and_Profitability_Snapshot\"><\/span><strong>Kopran vs Syncom Formulations (India) vs Shree Ganesh Remedies: Valuation and Profitability Snapshot<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Metric<\/th>\n<th><a href=\"https:\/\/univest.in\/stocks\/kopran\/kopran-ltd-share-price-today\">Kopran<\/a><\/th>\n<th><a href=\"https:\/\/univest.in\/stocks\/syncomf\/syncom-formulations-(india)-ltd-share-price-today\">Syncom Formulations (India)<\/a><\/th>\n<th><a href=\"https:\/\/univest.in\/stocks\/sgrl\/shree-ganesh-remedies-ltd-share-price-today\">Shree Ganesh Remedies<\/a><\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Market Cap (approx.)<\/td>\n<td>Rs 1,227 crore<\/td>\n<td>Rs 2,217 crore<\/td>\n<td>Rs 907 crore<\/td>\n<\/tr>\n<tr>\n<td>PE Ratio (TTM)<\/td>\n<td>49.10<\/td>\n<td>25.91<\/td>\n<td>58.77<\/td>\n<\/tr>\n<tr>\n<td>PB Ratio<\/td>\n<td>2.31<\/td>\n<td>5.34<\/td>\n<td>5.56<\/td>\n<\/tr>\n<tr>\n<td>Return on Equity (ROE)<\/td>\n<td>4.85%<\/td>\n<td>18.42%<\/td>\n<td>10.90%<\/td>\n<\/tr>\n<tr>\n<td>EPS (TTM, Rs)<\/td>\n<td>5.17<\/td>\n<td>0.91<\/td>\n<td>12.02<\/td>\n<\/tr>\n<tr>\n<td>Dividend Yield<\/td>\n<td>1.18%<\/td>\n<td>0.42%<\/td>\n<td>0.00%<\/td>\n<\/tr>\n<tr>\n<td>Debt to Equity<\/td>\n<td>0.29<\/td>\n<td>0.00<\/td>\n<td>0.19<\/td>\n<\/tr>\n<tr>\n<td>Book Value per Share (Rs)<\/td>\n<td>109.74<\/td>\n<td>4.41<\/td>\n<td>126.95<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check the Univest Screener for Live Data<\/strong><\/a><\/p>\n<p>On valuation, Kopran trades at a PE of 49.10 and a PB of 2.31, Syncom Formulations (India) at a PE of 25.91 and a PB of 5.34, while Shree Ganesh Remedies trades at a PE of 58.77 and a PB of 5.56. On return on equity, the three post 4.85%, 18.42% and 10.90% respectively, and on dividend yield they stand at 1.18%, 0.42% and 0.00%. Syncom Formulations (India) has the highest market capitalisation of the three at Rs 2,217 crore, while Shree Ganesh Remedies has the lowest at Rs 907 crore. Shree Ganesh Remedies has the highest PE ratio of the three at 58.77, while Syncom Formulations (India) has the lowest at 25.91. Syncom Formulations (India) has the highest return on equity of the three at 18.42%, while Kopran has the lowest at 4.85%. Kopran has the highest debt to equity ratio of the three at 0.29, while Syncom Formulations (India) has the lowest at 0.00. Debt to equity is 0.29, 0.00 and 0.19 for the three respectively.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Kopran_vs_Syncom_Formulations_India_vs_Shree_Ganesh_Remedies_Latest_Quarterly_Results\"><\/span><strong>Kopran vs Syncom Formulations (India) vs Shree Ganesh Remedies: Latest Quarterly Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Company<\/th>\n<th>Latest Quarter Revenue<\/th>\n<th>Latest Quarter Net Profit<\/th>\n<th>YoY Change (Revenue)<\/th>\n<th>QoQ Change (Revenue)<\/th>\n<th>YoY Change (Net Profit)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Kopran<\/td>\n<td>Rs 156.04 crore<\/td>\n<td>Rs 6.70 crore<\/td>\n<td>+13.3%<\/td>\n<td>-33.3%<\/td>\n<td>-10.1%<\/td>\n<\/tr>\n<tr>\n<td>Syncom Formulations (India)<\/td>\n<td>Rs 133.36 crore<\/td>\n<td>Rs 24.85 crore<\/td>\n<td>+8.5%<\/td>\n<td>-11.1%<\/td>\n<td>+57.8%<\/td>\n<\/tr>\n<tr>\n<td>Shree Ganesh Remedies<\/td>\n<td>Rs 15.30 crore<\/td>\n<td>Rs 1.12 crore<\/td>\n<td>-39.6%<\/td>\n<td>-55.3%<\/td>\n<td>-67.5%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Quarterly figures above are the most recent reported quarter for each company (Q1 FY27, quarter ended June 2026), compared with the year-ago and preceding quarter. A percentage change in net profit is shown as NA where the comparison quarter was a loss or the latest quarter is a loss, since the percentage is not meaningful in that case.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Kopran_vs_Syncom_Formulations_India_vs_Shree_Ganesh_Remedies_Five-Quarter_Revenue_and_Net_Profit_Trend\"><\/span><strong>Kopran vs Syncom Formulations (India) vs Shree Ganesh Remedies: Five-Quarter Revenue and Net Profit Trend<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The five-quarter view below shows how revenue and net profit moved from June 2025 to June 2026 for each company in Kopran vs Syncom Formulations (India) vs Shree Ganesh Remedies, which helps separate a one-quarter move from a steadier pattern.<\/p>\n<p><strong>Quarterly revenue (Rs crore)<\/strong><\/p>\n<table>\n<thead>\n<tr>\n<th>Quarter<\/th>\n<th>Kopran<\/th>\n<th>Syncom Formulations (India)<\/th>\n<th>Shree Ganesh Remedies<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>June 2025<\/td>\n<td>Rs 137.78 crore<\/td>\n<td>Rs 122.93 crore<\/td>\n<td>Rs 25.33 crore<\/td>\n<\/tr>\n<tr>\n<td>September 2025<\/td>\n<td>Rs 117.94 crore<\/td>\n<td>Rs 126.97 crore<\/td>\n<td>Rs 31.01 crore<\/td>\n<\/tr>\n<tr>\n<td>December 2025<\/td>\n<td>Rs 194.35 crore<\/td>\n<td>Rs 120.64 crore<\/td>\n<td>Rs 21.77 crore<\/td>\n<\/tr>\n<tr>\n<td>March 2026<\/td>\n<td>Rs 234.11 crore<\/td>\n<td>Rs 149.96 crore<\/td>\n<td>Rs 34.22 crore<\/td>\n<\/tr>\n<tr>\n<td>June 2026<\/td>\n<td>Rs 156.04 crore<\/td>\n<td>Rs 133.36 crore<\/td>\n<td>Rs 15.30 crore<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Quarterly net profit (Rs crore)<\/strong><\/p>\n<table>\n<thead>\n<tr>\n<th>Quarter<\/th>\n<th>Kopran<\/th>\n<th>Syncom Formulations (India)<\/th>\n<th>Shree Ganesh Remedies<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>June 2025<\/td>\n<td>Rs 7.45 crore<\/td>\n<td>Rs 15.75 crore<\/td>\n<td>Rs 3.45 crore<\/td>\n<\/tr>\n<tr>\n<td>September 2025<\/td>\n<td>-Rs 9.92 crore<\/td>\n<td>Rs 16.60 crore<\/td>\n<td>Rs 4.96 crore<\/td>\n<\/tr>\n<tr>\n<td>December 2025<\/td>\n<td>Rs 9.34 crore<\/td>\n<td>Rs 18.91 crore<\/td>\n<td>Rs 3.09 crore<\/td>\n<\/tr>\n<tr>\n<td>March 2026<\/td>\n<td>Rs 18.87 crore<\/td>\n<td>Rs 25.17 crore<\/td>\n<td>Rs 6.27 crore<\/td>\n<\/tr>\n<tr>\n<td>June 2026<\/td>\n<td>Rs 6.70 crore<\/td>\n<td>Rs 24.85 crore<\/td>\n<td>Rs 1.12 crore<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Kopran reported revenue of Rs 137.78 crore in June 2025 and Rs 156.04 crore in June 2026, a change of +13.3% across the period. Its highest quarterly revenue in this window was Rs 234.11 crore in March 2026. Net profit stood at Rs 6.70 crore in June 2026, which is a net profit margin of 4.29%. Kopran reported a net loss in September 2025.<\/p>\n<p>Syncom Formulations (India) reported revenue of Rs 122.93 crore in June 2025 and Rs 133.36 crore in June 2026, a change of +8.5% across the period. Its highest quarterly revenue in this window was Rs 149.96 crore in March 2026. Net profit stood at Rs 24.85 crore in June 2026, which is a net profit margin of 18.63%.<\/p>\n<p>Shree Ganesh Remedies reported revenue of Rs 25.33 crore in June 2025 and Rs 15.30 crore in June 2026, a change of -39.6% across the period. Its highest quarterly revenue in this window was Rs 34.22 crore in March 2026. Net profit stood at Rs 1.12 crore in June 2026, which is a net profit margin of 7.32%.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"https:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"https:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Kopran, Syncom Formulations (India) and Shree Ganesh Remedies live prices.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_Should_Investors_Look_at_Beyond_These_Numbers\"><\/span><strong>What Should Investors Look at Beyond These Numbers?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Beyond the metrics above, investors comparing these three pharma and biotech names should track quarter-on-quarter revenue and margin trends, management commentary on demand and cost drivers, and factors specific to the segment such as regulatory approvals, export orders, raw material costs and capacity utilisation. A single-quarter snapshot can shift quickly, and smaller companies in particular can show wide swings from one quarter to the next.<\/p>\n<p>It also helps to read the latest quarterly filings and investor presentations of Kopran, Syncom Formulations (India) and Shree Ganesh Remedies directly, since the figures here come from standardised data and do not capture company-specific context such as one-time items, order timing or promoter actions.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Kopran vs Syncom Formulations (India) vs Shree Ganesh Remedies highlights how differently three companies in the same pharma and biotech segment can look across valuation, profitability and dividend metrics, even when operating in a similar space. This comparison does not declare a winner; investors should weigh these figures against their own research and risk appetite. Please read the disclaimer below before making any investment decision.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information as of October 2026 and may not reflect real-time prices. Please verify all data independently before making any investment decision. This comparison does not recommend or endorse any single stock over another; investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"FAQs_on_Kopran_vs_Syncom_Formulations_India_vs_Shree_Ganesh_Remedies\"><\/span><strong>FAQs on Kopran vs Syncom Formulations (India) vs Shree Ganesh Remedies<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_market_cap_difference_between_Kopran_Syncom_Formulations_India_and_Shree_Ganesh_Remedies\"><\/span><strong>What is the market cap difference between Kopran, Syncom Formulations (India) and Shree Ganesh Remedies?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> As of October 2026, Kopran has a market cap of approximately Rs 1,227 crore, Syncom Formulations (India) is at approximately Rs 2,217 crore, and Shree Ganesh Remedies is at approximately Rs 907 crore.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_PE_and_PB_ratios_of_Kopran_Syncom_Formulations_India_and_Shree_Ganesh_Remedies\"><\/span><strong>What are the PE and PB ratios of Kopran, Syncom Formulations (India) and Shree Ganesh Remedies?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> As of October 2026, the PE ratios stand at 49.10, 25.91 and 58.77 respectively, and the price to book ratios stand at 2.31, 5.34 and 5.56 respectively.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_of_the_three_has_the_highest_ROE\"><\/span><strong>Which of the three has the highest ROE?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Kopran, Syncom Formulations (India) and Shree Ganesh Remedies post ROE of 4.85%, 18.42% and 10.90% respectively as of October 2026. Syncom Formulations (India) has the highest return on equity of the three at 18.42%, while Kopran has the lowest at 4.85%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_of_these_three_stocks_pays_the_highest_dividend_yield\"><\/span><strong>Which of these three stocks pays the highest dividend yield?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Kopran, Syncom Formulations (India) and Shree Ganesh Remedies carry dividend yields of 1.18%, 0.42% and 0.00% respectively.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_debt_to_equity_ratio_for_Kopran_Syncom_Formulations_India_and_Shree_Ganesh_Remedies\"><\/span><strong>What is the debt to equity ratio for Kopran, Syncom Formulations (India) and Shree Ganesh Remedies?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Kopran carries a debt to equity of 0.29, Syncom Formulations (India) of 0.00, and Shree Ganesh Remedies of 0.19.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_were_the_latest_quarterly_revenue_and_net_profit_of_Kopran_Syncom_Formulations_India_and_Shree_Ganesh_Remedies\"><\/span><strong>What were the latest quarterly revenue and net profit of Kopran, Syncom Formulations (India) and Shree Ganesh Remedies?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> For Q1 FY27 (quarter ended June 2026), Kopran reported revenue of Rs 156.04 crore and net profit of Rs 6.70 crore, Syncom Formulations (India) reported revenue of Rs 133.36 crore and net profit of Rs 24.85 crore, and Shree Ganesh Remedies reported revenue of Rs 15.30 crore and net profit of Rs 1.12 crore.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Does_this_comparison_recommend_one_of_Kopran_Syncom_Formulations_India_and_Shree_Ganesh_Remedies\"><\/span><strong>Does this comparison recommend one of Kopran, Syncom Formulations (India) and Shree Ganesh Remedies?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This comparison does not declare one stock ahead of another; each company scores differently across valuation, profitability and dividend metrics, and the right fit depends on an individual investor&#8217;s own criteria and research.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What is the market cap difference between Kopran, Syncom Formulations (India) and Shree Ganesh Remedies?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"As of October 2026, Kopran has a market cap of approximately Rs 1,227 crore, Syncom Formulations (India) is at approximately Rs 2,217 crore, and Shree Ganesh Remedies is at approximately Rs 907 crore.\"}},{\"@type\":\"Question\",\"name\":\"What are the PE and PB ratios of Kopran, Syncom Formulations (India) and Shree Ganesh Remedies?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"As of October 2026, the PE ratios stand at 49.10, 25.91 and 58.77 respectively, and the price to book ratios stand at 2.31, 5.34 and 5.56 respectively.\"}},{\"@type\":\"Question\",\"name\":\"Which of the three has the highest ROE?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Kopran, Syncom Formulations (India) and Shree Ganesh Remedies post ROE of 4.85%, 18.42% and 10.90% respectively as of October 2026. Syncom Formulations (India) has the highest return on equity of the three at 18.42%, while Kopran has the lowest at 4.85%.\"}},{\"@type\":\"Question\",\"name\":\"Which of these three stocks pays the highest dividend yield?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Kopran, Syncom Formulations (India) and Shree Ganesh Remedies carry dividend yields of 1.18%, 0.42% and 0.00% respectively.\"}},{\"@type\":\"Question\",\"name\":\"What is the debt to equity ratio for Kopran, Syncom Formulations (India) and Shree Ganesh Remedies?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Kopran carries a debt to equity of 0.29, Syncom Formulations (India) of 0.00, and Shree Ganesh Remedies of 0.19.\"}},{\"@type\":\"Question\",\"name\":\"What were the latest quarterly revenue and net profit of Kopran, Syncom Formulations (India) and Shree Ganesh Remedies?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"For Q1 FY27 (quarter ended June 2026), Kopran reported revenue of Rs 156.04 crore and net profit of Rs 6.70 crore, Syncom Formulations (India) reported revenue of Rs 133.36 crore and net profit of Rs 24.85 crore, and Shree Ganesh Remedies reported revenue of Rs 15.30 crore and net profit of Rs 1.12 crore.\"}},{\"@type\":\"Question\",\"name\":\"Does this comparison recommend one of Kopran, Syncom Formulations (India) and Shree Ganesh Remedies?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This comparison does not declare one stock ahead of another; each company scores differently across valuation, profitability and dividend metrics, and the right fit depends on an individual investor's own criteria and research.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Kopran vs Syncom Formulations (India) vs Shree Ganesh Remedies compared on market cap, PE, PB, ROE, dividend yield and debt to equity, as of October 2026.<\/p>\n","protected":false},"author":38,"featured_media":305120,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[10016,1019],"class_list":["post-305121","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market","tag-pharma-and-biotech","tag-stock-market"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["305120"],"rank_math_title":["Kopran vs Syncom Formulations (India) vs Shree Ganesh Remedies"],"rank_math_description":["Kopran vs Syncom Formulations (India) vs Shree Ganesh Remedies compared on market cap, PE, PB, ROE, dividend yield and debt to equity, as of October 2026."],"rank_math_focus_keyword":["Kopran vs Syncom Formulations (India) vs Shree Ganesh Remedies"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/10\/kopran-vs-syncom-formulations-vs-shree-ganesh-remedies-which-stock-should-you.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/305121","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/38"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=305121"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/305121\/revisions"}],"predecessor-version":[{"id":305122,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/305121\/revisions\/305122"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/305120"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=305121"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=305121"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=305121"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}